Scientist creates new cancer drug that is ten times more potent

August 29, 2012
Lee and his research team used carboranes to create a new cancer drug that is 10 times more potent than current cancer-fighting drugs. Credit: Nathan Hurst/University of Missouri

Legend has it that Ralph Waldo Emerson once said, "Build a better mousetrap, and the world will beat a path to your door." University of Missouri researchers are doing just that, but instead of building mousetraps, the scientists are targeting cancer drugs. In a new study, MU medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer, added a special structure to it, and created a more potent, efficient weapon against cancer.

"Over the past decade, we have seen an increasing interest in using carboranes in drug design," said Mark W. Lee Jr., assistant professor of chemistry in College of Arts and Science. "Carboranes are clusters of three elements—, carbon and hydrogen. Carboranes don't fight cancer directly, but they aid in the ability of a drug to bind more tightly to its target, creating a more potent mechanism for destroying the ."

In the study, Lee and his research team used carboranes to build new drugs designed to shut off a cancer cell's energy production, which is vital for the cell's survival. All cells produce energy through complex, multi-step processes. The key to an effective drug is targeting the process that cancer cells depend on more than healthy cells. By increasing the of a drug, a smaller dose is required, minimizing side effects and increasing the effectiveness of the therapy. With carboranes, Lee found that the drug is able to bind 10 times more powerfully.

The video will load shortly
Mark W. Lee Jr., an assistant professor of chemistry at the University of Missouri, and his research team have used carboranes to enhance cancer-fighting drugs. They recently created one drug that is 10 times more potent than current cancer-fighting drugs. The technology could be used to address other problems such as migraine headaches or Alzheimer's. Credit: Nathan Hurst/University of Missouri

"The reason why these drugs bind stronger to their target is because carboranes exploit a unique and very strong form of hydrogen bonding, the strongest form of interactions for drugs," Lee said.

Lee said that this discovery also will lead to further uses for the drug.

"Too often, after radiation or , cancer cells repair themselves and reinvade the body," Lee said. "This drug not only selectively shuts off the for the cancer cells, but it also inhibits the processes that allow those cancer cells to repair themselves. When we tested our carborane-based drugs, we found that they were unimaginably potent. So far, we have tested this on breast, lung and colon cancer, all with exceptional results."

According to Lee, this is the first study to show systematically how carboranes can improve the activity of a drug. Lee believes this discovery will open additional possibilities of improving drugs that are used to treat other diseases, not just cancer.

"The end result is that these could be many thousands of times more potent than the drugs that are used in the clinics today," Lee said.

While it will be several years before the new drug would be available on the market, Lee said that clinical trials could begin within the next two years. Additionally, further testing on other is underway. The study was published in the Journal of Medicinal Chemistry, a publication of the American Chemical Society.

Explore further: Discovery could reduce chemotherapy's side effects

Related Stories

Discovery could reduce chemotherapy's side effects

March 11, 2012
A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy ...

New ruthenium-based drugs show promise for killing cancer cells

June 11, 2012
A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

Protein 'switches' could turn cancer cells into tiny chemotherapy factories

September 23, 2011
Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Smarrelli
not rated yet Aug 30, 2012
This sounds incredible. A couple of questions though..

I don't think I saw it mentioned in the article, but how would the drug be administered? Tablet, injection etc.

Secondly, where would this drug fit in the general approach to treating cancer? Would it be used in conjunction with chemo? i.e. taken after chemo to prevent the reparation of cancer cells, or could this be an alternative to chemo depending on the type, and progression of the cancer?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.